Sorafenib fails to trigger ferroptosis across a wide range of cancer cell lines.
Cell Death Dis. 12:698 (2021)
Sorafenib, a protein kinase inhibitor approved for the treatment of hepatocellular carcinoma and advanced renal cell carcinoma, has been repeatedly reported to induce ferroptosis by possibly involving inhibition of the cystine/glutamate antiporter, known as system xc-. Using a combination of well-defined genetically engineered tumor cell lines and canonical small molecule ferroptosis inhibitors, we now provide unequivocal evidence that sorafenib does not induce ferroptosis in a series of tumor cell lines unlike the cognate system xc- inhibitors sulfasalazine and erastin. We further show that only a subset of tumor cells dies by ferroptosis upon sulfasalazine and erastin treatment, implying that certain cell lines appear to be resistant to system xc- inhibition, while others undergo ferroptosis-independent cell death. From these findings, we conclude that sorafenib does not qualify as a bona fide ferroptosis inducer and that ferroptosis induced by system xc- inhibitors can only be achieved in a fraction of tumor cell lines despite robust expression of SLC7A11, the substrate-specific subunit of system xc-.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Editors
Keywords
X(c)(-) Cystine Transporter; Plasma-membrane; Death; Inhibition; Resistance; Exchange; Growth
Keywords plus
Language
english
Publication Year
2021
Prepublished in Year
HGF-reported in Year
2021
ISSN (print) / ISBN
2041-4889
e-ISSN
2041-4889
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 12,
Issue: 7,
Pages: ,
Article Number: 698
Supplement: ,
Series
Publisher
Nature Publishing Group
Publishing Place
Campus, 4 Crinan St, London, N1 9xw, England
Day of Oral Examination
0000-00-00
Advisor
Referee
Examiner
Topic
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
POF-Topic(s)
30203 - Molecular Targets and Therapies
Research field(s)
Genetics and Epidemiology
PSP Element(s)
G-506900-001
Grants
Deutsche Forschungsgemeinschaft (German Research Foundation)
Copyright
Erfassungsdatum
2021-08-04